Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality’s B7H4 targeted antibody-drug conjugate (ADC), DB1312/BG-C9074.
Terms of the Agreement and Financials
The exclusive option was initially granted to BeiGene in July 2023, allowing them to obtain a global clinical and commercial license for an investigational, preclinical ADC therapy intended for patients with select solid tumors. As part of the deal, Duality Biologics received an upfront payment and is eligible for additional payments upon the achievement of specific development, regulatory, and commercial milestones, totaling up to USD1.3 billion. This financial arrangement also includes tiered royalties on sales.
Recent Milestone Achievements
In the current year, Duality Biologics has received an option exercise fee and a milestone payment based on the advancement of Phase I dose-escalation for DB1312/BG-C9074. This progress underscores the momentum behind the development of the ADC and the potential for it to become a significant treatment option for patients with solid tumors.-Fineline Info & Tech
